1. Home
  2. BRCA1
  Subject:

BRCA1   New Search

View on DBpedia    View on Wikipedia
Top related subjects:
RELATED SUBJECTS:
The publications listed also have these subjects
Breast cancer  29 times
BRCA2  25 times
Ovarian cancer  18 times
DNA  15 times
Gene  14 times
Homologous recombination  8 times
Protein  6 times
Polymerase  6 times
Estrogen receptor  6 times
Adenosine diphosphate ribose  6 times
DNA repair  5 times
Chemotherapy  5 times
TNBC  4 times
Polymerase chain reaction  4 times
P53  4 times
Mastectomy  4 times
Hormone  4 times
DNA sequencing  4 times
Phenotype  3 times
Mammography  3 times
Magnetic resonance imaging  3 times
Intron  3 times
Biomarker  3 times
Western blot  2 times
Triple-negative breast cancer  2 times
Toll-like receptor  2 times
Tamoxifen  2 times
Sensitivity analysis  2 times
Radiation therapy  2 times
RAD51  2 times
Progesterone receptor  2 times
Prime Time Entertainment Network  2 times
P16  2 times
Non-small-cell lung carcinoma  2 times
Neu!  2 times
Mutation  2 times
Mitogen-activated protein kinase  2 times
Metastasis  2 times
MSH2  2 times
MLH1  2 times
Lymph node  2 times
Logistic regression  2 times
Invasive carcinoma of no special type  2 times
In silico  2 times
Immunohistochemistry  2 times
Histology  2 times
Genetic counseling  2 times
Fallopian tube  2 times
Exon  2 times
Bone marrow  2 times
Autophagy  2 times
Apoptosis  2 times
Acid  2 times
Zeta potential  1 time
World Health Organization  1 time
White blood cell  1 time
WT1  1 time
Trimethoxyamphetamine  1 time
Transferase  1 time
Transcriptome  1 time
Transcription factor  1 time
Tissue microarray  1 time
Tissue engineering  1 time
Time  1 time
TMZ  1 time
TLR2  1 time
Systems biology  1 time
Syndrome  1 time
Swedish language  1 time
Stop codon  1 time
Spectroscopy  1 time
Sanger sequencing  1 time
Romantic Times  1 time
Rochester Red Wings  1 time
Ribose  1 time
Reverse transcriptase  1 time
Reporter gene  1 time
Real-time polymerase chain reaction  1 time
Quantum  1 time
Pyrosequencing  1 time
Pyrene  1 time
Purine  1 time
Protein–protein interaction  1 time
Peroxisome proliferator-activated receptor  1 time
Perineural invasion  1 time
Pancreatic cancer  1 time
Paclitaxel  1 time
Ovulation  1 time
Oncology  1 time
Omega-3 fatty acid  1 time
O-6-methylguanine-DNA methyltransferase  1 time
Nucleotide  1 time
Necrosis  1 time
National Comprehensive Cancer Network  1 time
National Cancer Institute  1 time
Myc  1 time
Munhwa Broadcasting Corporation  1 time
Monte Carlo method  1 time
Microarray  1 time
Metabolite  1 time
Metabolism  1 time
Messenger RNA  1 time
Mesothelioma  1 time
Medical record  1 time
Mdm2  1 time
Mayo Clinic  1 time
Markov chain  1 time
Malaysia  1 time
MCF-7  1 time
MAPK3  1 time
Lung cancer  1 time
Luciferase  1 time
Long non-coding RNA  1 time
List of breast cancer cell lines  1 time
Linux.conf.au  1 time
Kyoto University  1 time
KRAS  1 time
KEGG  1 time
Japan  1 time
Israel  1 time
Intraclass correlation  1 time
Insulin-like growth factor 1 receptor  1 time
Insulin receptor  1 time
Insulin  1 time
Incremental cost-effectiveness ratio  1 time
Iatrogenesis  1 time
IC50  1 time
Hsp90  1 time
Hospital  1 time
Hispanic and Latino Americans  1 time
High-performance liquid chromatography  1 time
Gonadotropin-releasing hormone  1 time
Genome  1 time
Gene set enrichment analysis  1 time
Gene regulatory network  1 time
Frameshift mutation  1 time
Fluorescence  1 time
Fatty acid  1 time
Estrogen receptor alpha  1 time
Epithelium  1 time
Epigenetics  1 time
Enzyme inhibitor  1 time
Enzyme  1 time
Endometrial cancer  1 time
Emission spectrum  1 time
Electron transport chain  1 time
Egypt  1 time
Effusion  1 time
EP300  1 time
Disease  1 time
Decision model  1 time
DNA mismatch repair  1 time
DNA methylation  1 time
Czech Republic  1 time
Cytopathology  1 time
Cyclophosphamide  1 time
Cyclin-dependent kinase 4  1 time
Cyclin-dependent kinase 2  1 time
Confocal microscopy  1 time
Confidence interval  1 time
Complete blood count  1 time
Complementary DNA  1 time
Comparative genomic hybridization  1 time
Comet assay  1 time
Cluster analysis  1 time
ClinicalTrials.gov  1 time
Clinical trial  1 time
Classical mechanics  1 time
Cisplatin  1 time
Chromatin  1 time
Chi-squared test  1 time
Chain reaction  1 time
Cell cycle  1 time
Caspase  1 time
Carotene  1 time
Carcinoma  1 time
Carboxylic acid  1 time
Capecitabine  1 time
Calcitriol receptor  1 time
C-reactive protein  1 time
Blood plasma  1 time
Before Present  1 time
Bcl-2  1 time
Axillary lymph nodes  1 time
Ataxia telangiectasia and Rad3 related  1 time
Ant colony  1 time
Adjuvant  1 time
Adenosine triphosphate  1 time
Acute myeloid leukemia  1 time

Publications tagged with this subject: 50

Note: Top 50 publications shown only. Open an item panel to view more info


1. Cells of origin of ovarian cancer: ovarian surface epithelium or fallopian tube?

2. Spectrum of genetic variants of BRCA1 and BRCA2 in a German single center study

3. Comprehensive strategy for the design of precision drugs and identification of genetic signature behind proneness of the disease—a pharmacogenomic approach

4. Validation of the German version of the Mediterranean Diet Adherence Screener (MEDAS) questionnaire

5. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer

6. Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer

7. Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment

8. Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation

9. Novel BRCA1 splice-site mutation in ovarian cancer patients of Slavic origin

10. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance

11. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population

12. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages

13. A single visit multidisciplinary model for managing patients with mutations in moderate and high-risk genes in a community practice setting

14. FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices

15. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing

16. Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing

17. Our genes, our selves: hereditary breast cancer and biological citizenship in Norway

18. Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients

19. Structural Insight into the Mechanism of Dibenzo[a,l]pyrene and Benzo[a]pyrene-Mediated Cell Proliferation Using Molecular Docking Simulations

20. BRCA1 gene: function and deficiency

21. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells

22. Assessment of in silico protein sequence analysis in the clinical classification of variants in cancer risk genes

23. HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation

24. BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial

25. Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis

26. Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes

27. Exploiting Homologous Recombination Deficiency in TNBC

28. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients

29. Recent insights into the molecular basis of Fanconi anemia: genes, modifiers, and drivers

30. Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients

31. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer

32. When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges

33. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion

34. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia

35. The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy

36. Cytological diagnosis of malignant pleural mesothelioma

37. Simultaneous ATM/BRCA1/RAD51 expression variations associated with prognostic factors in Iranian sporadic breast cancer patients

38. Identification and Characterization of a New BRCA2 Rearrangement in an Italian Family with Hereditary Breast and Ovarian Cancer Syndrome

39. In silico identification of potential key regulatory factors in smoking-induced lung cancer

40. Video Education on Hereditary Breast and Ovarian Cancer (HBOC) for Physicians: an Interventional Study

41. Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications

42. BRCA2 carriers with male breast cancer show elevated tumour methylation

43. The role of screening MRI in the era of next generation sequencing and moderate-risk genetic mutations

44. Differential long noncoding RNA/mRNA expression profiling and functional network analysis during osteogenic differentiation of human bone marrow mesenchymal stem cells

45. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature

46. BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells

47. Inherited predisposition to breast and ovarian cancer in non-Jewish populations in Israel

48. CdSe Quantum Dots Based Nano-Biosensor for Detection of 185delAG Mutation in BRCA1 Gene, Responsible for Breast Cancer

49. Is there a genetic anticipation in breast and/or ovarian cancer families with the germline c.3481_3491del11 mutation?

50. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers


Questions?

Drop us a message.